You searched for "BPO"

100 results found

‘Born in the USA’ – neonatal circumcision

In 2006, the British Association of Paediatric Urologists (BAPU) published a statement paper on the management of foreskin conditions (www.baps.org.uk/resources/management-foreskin-conditions). Non-therapeutic circumcisions (those to comply with religious or cultural practices) are not uniformly available on the NHS. Circumcisions for medical...

Can we make LATE-presenting posterior urethral valves an EARLIER-treated condition?

What are posterior urethral valves? Posterior urethral valve (PUV) is the most common cause of congenital bladder outlet obstruction (BOO) and renal failure in male children. They were first described by the Italian anatomist Giovanni Battista Morgagni back in the...

Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update

The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...

Practice makes perfect – but does the HoLEP learning curve affect sexual function?

This article poses an interesting question: whilst we know there is an association with HoLEP and ejaculatory dysfunction (BAUS quotes a 90% risk for retrograde ejaculation), is this risk dependent on surgeon experience and their learning curve with HoLEP? This...

Prostatic artery embolisation versus sham

Randomised trials with use of sham is uncommon in the surgical literature, which makes this paper more interesting. Many different treatments are available for treating lower urinary tract symptoms / benign prostatic hyperplasia (LUTS / BPH). Prostatic artery embolisation (PAE)...

ICS updates on continence care: making sense of detrusor underactivity and the underactive bladder

Countless epidemiological studies have established the frequent occurrence of lower urinary tract symptoms (LUTS) and the significant burden these symptoms incur. For the most part of the past three decades, there has been an overwhelming focus on detrusor overactivity (DO)...

NOVOGLAN – Conservative Phimosis Management

iMEDicare are pleased to introduce Novoglan, an evidence-based, non-surgical solution for adult phimosis, now available as a reimbursable outpatient treatment under the NHS OPCS-4 code N30.5 (Stretching of the Prepuce), which maps to HRG LB56A. This presents an exciting opportunity...

Consent

See Part 2 on this topic here Case 1 A 15-year-old boy attends with his father to have a circumcision on a day case list. He had been seen previously by a colleague and noted to have a tight phimosis...

Supporting chronic cystitis patients through the winter

The current pandemic is causing severe disruption to the care of patients with non-life-threatening conditions.

PDE5I in LUTS – how do they work – no proof yet

Phosphodiesterase type 5 (PDE5) inhibitors used in erectile dysfunction (ED) have been shown to improve lower urinary tract symptoms (LUTS) as well. The mechanism is not well understood. One of the hypotheses for benign prostatic hyperplasia (BPH) – LUTS is...

Prostate size in transwomen on gender-affirming hormone therapy

This study examined prostate size and characteristics in transgender females (TF) receiving hormone therapy (HT) and androgen deprivation (AD). Although gender-affirming surgery may include orchiectomy and vaginoplasty, most TF and gender-nonconforming individuals who were assigned male at birth retain their...

Prostate artery embolisation

Introduction Benign prostatic hyperplasia (BPH), a common condition associated with ageing, affects 50% of those between the ages of 50 and 60 years, and as many as 90% of those older than 80 years. BPH is characterised by unregulated, benign...